Spyre Therapeutics, Inc. SYRE Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s change in AP?
- Spyre Therapeutics, Inc. (SYRE) reported change in AP of -$3.21M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s change in AP changed year-over-year?
- Spyre Therapeutics, Inc.'s change in AP decreased by 206.3% year-over-year, from $3.02M to -$3.21M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s change in AP?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s change in AP has grown at a 97.8% compound annual growth rate (CAGR), from $1.07M to $8.24M.
- What does change in AP mean?
- Measures the net change in obligations owed to suppliers and vendors for goods and services received. An increase indicates that the company is retaining cash longer by delaying payments, while a decrease indicates the settlement of outstanding liabilities. It is a key indicator of short-term liquidity management and supplier relationship dynamics.